EICHOR
● Active Not Recruiting
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Condition: NSCLC, Stage IB-IIIA · Lung Cancer · Adjuvant · Sponsor: Taiho Oncology, Inc.
About this study
The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (252)
| Alaska Oncology and Hematology | Anchorage, Alaska, United States | — |
| City of Hope Comprehensive Cancer Center - Duarte | Duarte, California, United States | — |
| City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center | Irvine, California, United States | — |
| Scripps Clinic Torrey Pines | La Jolla, California, United States | — |
| Kaiser Permanente - Vallejo Medical Center | Vallejo, California, United States | — |
| Georgetown University School of Medicine | Washington D.C., District of Columbia, United States | — |
| D&H Cancer Research Center - Margate | Margate, Florida, United States | — |
| Alpha Oncology Research | Orange City, Florida, United States | — |
| City of Hope - Atlanta | Newnan, Georgia, United States | — |
| University of Illinois Medical Center | Chicago, Illinois, United States | — |
| Profound Research LLC at Michigan Hematology and Oncology Consultants | Dearborn, Michigan, United States | — |
| Henry Ford Health System | Detroit, Michigan, United States | — |
+ 240 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07128199